PHMB PharmaCom BioVet Inc (CE)

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce that it is executing a Joint Venture Agreement with a research development company with an intellectual property portfolio. The purpose of this Joint Venture Agreement is to finalize the development of a compound which has the potential to become a viable treatment of specific cancers for companion animals within the veterinary marketplace.

The compound is in the family of Histone Deacetylase (HDAC) inhibitors, which binds directly to the catalytic site of the enzyme thereby potentially blocking the substrate access. This compound could have the ability to inhibit class I and class II HDACs and potentially arrest cellular growth in a wide variety of transformed cells.

The Company will be initially focused on targeted research and developmental activities on a very specific canine tumor type commonly found in the canine population with a view to commercializing any potential positive results.

About us:

PharmaCom BioVet, Inc. is quickly positioning itself to becoming the leader in specialized veterinary oncology (cancer treatment facilities for animals). PHMB management is planning the rollout of specialized Veterinary Oncology Treatment Centers that will be strategically located throughout the United States. PHMB has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer a potentially greater life expectancy and decreased suffering.

Mr. Gary Berthold
President, CEO

DISCLOSURE:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

Contact: Investor Relations Tel: (919) 701-4574 Url: http://www.PharmaComBioVet.com